An 1850 Sea Tragedy in Kilkee – Ireland s Own irelandsown.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from irelandsown.ie Daily Mail and Mail on Sunday newspapers.
Spotlight: A writer’s love affair with Limerick
Reporter: );
);
Frances Browner’s poetry has been featured on Limerick’s Poetry Trail, Poetry Walls and ‘Bring your Limericks to Limerick’.
Although she grew up in Dublin, lived in New York for twenty years and now resides in Greystones, Co. Wicklow, her family connections with Limerick city are strong and her heart is very much connected with Limerick. Her poems have appeared in several magazines including The Ogham Stone (the University of Limerick literary journal). She has also had short stories and memoir pieces published and broadcast on radio.
Grandfather
Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
February 15, 2021 GMT
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal
BioDrugs has published results from REVEAL, the Phase I/IIa clinical trial that evaluated the safety of LUMEVOQ ® gene therapy in subjects with
ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the Phase III trials RESCUE and REVERSE.
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal
BioDrugs has published results from REVEAL, the Phase I/IIa clinical trial that evaluated the safety of LUMEVOQ
® gene therapy in subjects with
ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the Phase III trials RESCUE and REVERSE.
The paper , published in the February issue of
BioDrugs under the title “Safety of intravitreal gene therapy for treatment of subjects with Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial